Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of MK-3682B in Renal Insufficiency
NCT02661126Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of uprifosbuvir, grazoprevir and ruzasvir in hepatitis C (HCV) (3 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Plasma Concentration-time Curve From Dosing to Time of Last Measurable Concentration, Area Under the Plasma Concentration-time Curve From Dosing to Infinity and 5 more. Started Jan 2016; status: completed.
02
Drugs
uprifosbuvirgrazoprevirruzasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02661126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661126.